Associations of HLA-DR and HLA-DQ types with anti-GBM nephritis by sequence-specific oligonucleotide probe hybridization  by Huey, B.i.n.g. et al.
Kidney International, Vol. 44 (1993), PP. 307—312
Associations of HLA-DR and HLA-DQ types with anti-GBM
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Associations of HLA-DR and HLA.DQ types with anti-GBM nephritis
by sequence-specific oligonucleotide probe hybridization. Twenty-three
patients from the United States with anti-glomerular basement mem-
brane nephritis (Goodpasture's syndrome) were HLA class I and class
II typed by serology and HLA-DR and HLA-DQB typed using se-
quence-specific oligonucleotide (SSO) probes. Protocols used were
those of the 11th International HLA Workshop. We were able to
confirm the strong association of DR2 with the disease and, using the
molecular techniques, showed that all DR2 patients were restricted to
DRB1-1501 and DQB1-0602 alleles. We also found highly significant
associations between disease and the alleles of DRB1-0301 and DQB1-
0201. DR4 alleles as a group were not significantly more frequent among
patients, but the allele DRB1-0404 did appear to be associated with the
disease. The use of SSO typing provides an expanded opportunity for
refined analysis of HLA and disease associated alleles.
Immunogenetic associations can be seen in a number of
kidney diseases. In idiopathic membranous nephropathy signif-
icant increases in frequencies of HLA-B8 and HLA-DR3 have
been found [1, 2]. IgA nephropathy has been found in strong
association with DR4 in Japanese [3] and with DQ7 in Cauca-
sian populations [4]. Anti-glomerular basement membrane
(anti-GBM) nephritis defined by the presence of autoantibodies
in the circulation and bound to the GBM is a relatively rare form
of glomerulonephritis and, when accompanied by pulmonary
hemorrhage is termed Goodpasture's syndrome. Much work
has been done in the characterization of the autoantibody and in
defining its specificity [5, 6]. The target antigen(s) of the
autoantibody resides predominantly in the alpha 3 (IV) collagen
chain [7] of the GBM, and studies are defining the peptide
nature of the epitopes [8, 9]. Definition of the epitope(s) makes
this disease attractive for study as a model of autoimmune
disease in association with the major histocompatibility com-
plex (MHC).
The association between Goodpasture's syndrome and HLA
DR2 was initially reported [10, 11] to be highly significant based
upon serological data. More recently, the technique of DNA-
HLA typing by restriction fragment length polymorphisms
(RFLP) has been able to split DR2 into DR15 and DR16 [12].
Using this technique, Dunckley et al [13] demonstrated that the
DRI5 split of DR2 occurs more frequently in patients with
anti-GBM disease. The availability now of DNA sequence
information for virtually all recognized HLA Class II specific-
ities has allowed the development of sequence-specific oligonu-
cleotide probes (SSOPs) which precisely hybridize only to
specific DNA sequences in the hypervariable regions of the
HLA genes. These probes hybridize to and signal the presence
of particular sequences which are responsible for various
alleles. This technique, now most commonly applied to poly-
merase chain reaction (PCR)-amplified DNA, has permitted the
identification of many splits of HLA specificities. For HLA-DR
this has been accomplished by examination of the hypervariable
regions of the DR beta chain.
It was our intent to use these techniques to study a sample of
patients with anti-GBM nephritis. These patients resided in
various parts of the United States and were referred to the
Scripps Research Institute for determination of anti-GBM anti-
body levels. We were interested in examining the recently
described DNA typing splits of DR2 in this disease. With most
HLA class II specificities now subdivided into alleles, or
subtypes, by molecular typing we wanted to determine whether
the association was restricted to a particular DR2 subtype or
was heterogeneously distributed. DNA sequence information
inferred from molecular typing can be translated into amino
acid sequences for the HLA molecules which are involved in
processing of specific antigenic epitopes and, in turn, help to
regulate the induction of the immune response which is respon-
sible for this disease. Knowledge of the amino acid sequences
of different susceptibility alleles may help in understanding the
role of the HLA molecule in the etiology of anti-GBM nephritis.
Our data indicate the DR2 DRB-allele 1501 and the DQ1 allele
DQB-0602 as the alleles predominantly associated with anti-
GBM nephritis in our Caucasian population.
Methods
Patients
Patients suspected of having anti-GBM disease were referred
to the Scripps Clinic. The most recent 23 patients with con-
firmed anti-GBM nephritis who consented to participation were
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Table 1. Conditions recommended by the 11th International
Histocompatibility Workshop for PCR amplification of the MHC
Class II gene targets examined in this study
MgCI2
final
Condition Denaturation Annealing Extension concentration
B 96°C-30 sec. 55°C-i mm 72°C-i mm 2.0 ms
C 96°C-30 sec. 60°C-I mm 72°C-i mm 1.5 mM
Target gene Condition
DRB generic B
DR1-DRB1 C
DR2-DRB1 C
DR4-DRB1 C
DRw52-associated-DRB I (formerly C
DR3, DR5, DR6, DR8)
DRw52-DRB3 C
DQB B
included in this study. These 23 subjects were chosen for study
based on the presence of anti-giomerular basement membrane
antibodies and glomerulonephritis [141. They represented 13
females (Caucasian) and 10 males (7 Caucasian, 3 unknown).
Controls
Frequencies of alleles and haplotypes for the control U.S.
Caucasian population were obtained from the 11th International
Histocompatibiity Workshop (IHWS).
HLA serology
Serological typing for HLA-A, -B, -C, -DR, and -DQ antigens
was performed by the standard microlymphocytotoxicity assay
[15].
DNA typing
To determine the alleles of HLA-DR and -DQ antigens,
sequence specific oligonucleotide (SSO) probing of polymerase
chain reaction (PCR)-amplified DNA was performed [16]. SSO
typings were based on examination of the DRB 1 and DQB 1
chains by the 11th IHWS protocols. Typing entailed initial
probing by SSOs of the generically amplified DRB1 chain.
Based on these results samples were subjected to group-specific
amplification using primers designed to recognize specific allele
groups. The products of these amplifications were probed again
with SSOs to determine the allelic types. Generic DRB typing
also permitted the recognition of the DRB3 and DRB4 genes,
which code for the DR52 and DR53 determinants, respectively.
The conditions for PCR of MHC Class II target genes for the
generic and group specific amplification are given in Table 1.
Sequences for the primers used appear in Figure 1. SSO probes
were designed by the 11th IHWS to target hypervariable
regions of the DRB1 chain and the DQB1 chain, whose se-
quences are available in the study by Marsh and Bodmer [17].
DNA extraction
To prepare DNA, whole blood was centrifuged at 500 x g to
form a buffy coat which was retrieved and incubated overnight
at 55°C in STE (100 m NaCl, 10 ifiM Tris pH 7.0, 1 mrst EDTA)
containing 0.5% sodium dodecyl sulfate and 100 pg/nil protein-
ase K (Boehringer Mannheim, Germany). It was then extracted
Fig. 1. Sequences of the primers used for the DRBJ gene, generic and
group-spec(fic, and DQB amplifications as given by the 11th Interna-
tional Histocompatibility Workshop.
twice with phenol-chloroform-isoamyl alcohol (25:24:1) and
once with chloroform-isoamyl alcohol (24:1). Sodium acetate
was added to the last aqueous layer to a concentration of 0.3 M
and two volumes of ice cold ethanol were added. The mixture
was gently agitated and chilled at —20°C for at least two hours.
The DNA precipitate was pelleted by centnfugation at 4000 x g
for 20 minutes and drained of the ethanol. The pellet was
washed with 70% ethanol, repelleted, drained and resuspended
in TE (10 mr'.i Tris, pH 7.0, 1 mrt EDTA).
Amplification by PCR and hybridization by SSOs
Approximately 100 ng of DNA were used as template for
each polymerase chain reaction. Each reaction (50 l) also
contained buffer (50 mrs KC1, 10 m Tris, pH 9.0, 1.5 m or 2.0
mM MgC12, 0.01% gelatin, and 0.1% Triton X-100), deoxyribo-
nucleotides at 0.2 m each, primers at 0.5 /.M each, T4 gene 32
DRB Generic amplification--
DRBamp-A CCCCACAGCACG1TFCTFG
DRBamp-B CCGCTGCACTGTGAAGCTCT
DR1 Group-specific amplification--
DRBamp-1 TFCTFGTGGCAGCT1AAGTF
DRBamp-B same as above
DR2 Group-specification amplification--
DRBamp-2 TFCCTGTGGCAGCCTAAGAGG
DRBamp-B same as above
DR4 Group-specification amplification--
DRBamp-4 GTFTCTFGGAGCAGG1TAAAC
DRBamp-B same as above
DRw52-associated group-specification amplification--
DRBamp-3 CACG1TTCTFGGAGTACTCTAC
DRBamp-B same as above
DQB amplification---
DQBamp-A CATGTGCTACTFCACCAACGG
DQBamp-B CTGGTAG1TGTGTCTGCACAC
Huey ci al: HLA-DR and -DQ types in anti-GBM nephritis 309
protein at 0.2 p, and 1 unit Taq DNA polymerase. The volume
was brought up to 50 tl with water. Reaction conditions (Table
1), the primers for PCR amplification and the sequence-specific
oligonucleotides (S SOs) used for probing were those of the 11th
IHWS. Control DNAs were those from homozygous typing cell
lines [181.
To ensure that hybridization of probes would specifically be
to PCR products and not to contaminating or non-specific
targets, the PCR products were electrophoresed on 1% agarose
gels (ME, FMC) with TAE buffer (40 mt Tris-acetate, 1 mM
EDTA, pH 8.0), denatured, and transferred onto nylon mem-
branes (Hybond-N, Amersham) by a modified method of South-
ern blotting [19]. After transfer the membranes were baked
(80°C, 2 hr) and then prehybridized for a minimum of 20
minutes. The prehybridization solution consisted of 6x SSPE,
Sx Denhardt's solution [20], 0.1% sodium lauroylsarcosine,
and 0.2% sodium dodecyl sulfate. Hybridization of the mem-
branes was carried out for a minimum of two hours at 52°C in a
mixture consisting of prehybridization solution with labeled
SSOs at 2.5 pmollml. About 0.5 ml of hybridization solution
was used per cm2 of membrane. Following hybridization filters
were washed at room temperature in 2x SSPE followed by a
TMAC wash (3 M tetramethylammonium chloride, 50 mM
Tris-HC1, pH 8.0, 2 mrt EDTA, 0.1% SDS). They were then
washed twice for 15 minutes each in 58°C TMAC wash and then
again in room temperature 2x SSPE.
Probe labeling
SSO probes were labeled by tailing with digoxigenin-tagged
dUTP (Boehringer) using terminal transferase (Boehringer)
according to manufacturer's recommendations except that re-
action time was increased to 30 minutes.
Detection
Detection of hybridized probe was carried out essentially
according to manufacturer's recommendations (Genius system,
Boehringer) and included chemiluminescent signal detection
(Lumiphos-530, Boehringer). Hybridization signals were visu-
alized by exposure of the chemiluminescent-treated filter to
x-ray film (Kodak X-Omat) and scored according to intensity as
recommended by the 11th IHWS.
Results
Table 2 shows patient information and typing data in this
study. Of our 23 patients with anti-GBM disease five had
glomerulonephntis alone, three had glomerulonephritis with
questionable lung involvement, and fifteen were diagnosed with
full Goodpasture's syndrome. Since the anti-GBM antibody
titer typically falls and disappears from a few weeks to one to
two years after onset of disease, the level of antibody at
sampling relates to the duration of the disease. The anti-GBM
antibody titers are described as weakly positive, positive, or
strongly positive, representing the lower 25%, middle 50%, and
upper 25%, respectively, of the percent binding of radiolabelled
antigen relative to a positive control. All but five of the patients
in this group had kidney failure requiring dialysis.
By serological typing we found 20 patients to have DR2, nine
with DR3, seven with DR4, two with DR1, one with DR6, and
one with DR7. Consistent with usual observations of antigen
associations all DR3s were associated with DRS2 and all DR4s
and DR7 were associated with DR53. There were 21 patients
with DQ1, all but one appearing to also have DR2, and five with
DQ2. There were seven DQ3s and all of these were found in
patients having DR4.
DR2 can be split by molecular typing of the DRB I gene into
DRB1-150l, DRB1-l502, DRB1-1601, and DRB1-1602. Simi-
larly, DQ1 (DQw5 + DQw6) can be split into DQB1-0501,
DQB1-0502, DQB1-0503, DQB1-0601, DQB1-0602, DQB1-
0603, and DQB1-0604. By SSO typing we found that all DR2s
were of the type DRB1-1501, and these all had the DQB1-0602
split of DQ 1. All DR3s typed as DRB 1-0302, and these were
found in association with DQB 1-0201. DR4s were not uniformly
of one subtype. Four patients could be unambiguously typed as
DRB 1-0404, one as DRB 1-0403, and one as DRB 1-0401. Two
others could only be typed by generic DRB probing as DR4. All
DR4 patients, however, were found to have the same split of
DQ3, namely, DQB1-0302.
Observed and expected numbers of patients having the
different alleles seen in our patient population are shown in
Table 3. Haplotypes could not be confirmed by family studies,
but were inferred through the known common associations
through linkage disequilibrium of the alleles at the two loci and
also by the consistent occurrence of the allele pairs in our
patient population. Expected numbers based upon Hardy-
Weinberg equilibrium were derived from estimated frequencies
given for the U.S. population by the 11th IHWS. We were able
to confirm the strong association of DR2 with anti-GBM nephri-
tis while identifying DRBI-1501 as the SSOP-defined suscepti-
bility allele in our sample. While likely due in large part to
linkage disequilibrium with the DR locus, DQB1-0602 (DQ1)
was also seen to have strong association to the disease. The
entire presumed haplotype occurred more frequently with high
significance. The DRB 1-0301/DQB 1-0201 presumed haplotype
was significantly more common among our patients when
compared with estimated haplotype frequencies given by the
11th IHWS for the U.S. population. The DR4 group-specific
hybridization allowed us to detect a significant association of
one subtype, namely, DRB1-0404, with Goodpasture's,
whereas, as a group, DR4 alleles were not more common among
patients. Finally, there was no apparent correlation between
HLA-DRJDQ alleles and antibody levels, severity of illness, or
age of onset.
Discussion
We have been able to DNA-HLA type 23 patients having
anti-GBM antibody disease who presented a range of clinical
manifestations (Table 2). They were the most recent patients
referred to the Scripps clinic prior to the initiation of this study
who consented to giving blood for DNA isolation. There were
ten males and thirteen females, ranging in age of onset from
nine to 60 years, who were drawn from the United States
population. They were Caucasian with the exception of three
patients whose ethnicities were not determined. Our patient
population was comprised of individuals who had been referred
to a tertiary center for assessment of autoantibody status. Their
inclusion in this study was based on having glomerulonephritis
and possessing measurable titers of anti-glomerular basement
membrane antibodies. As a result, not all had a diagnosis of full
Goodpasture's syndrome, which would have indicated varying
310 Huey et a!: HLA-DR and -DQ types in anti-GBM nephritis
Table 2. Summary of patient information and typing data by SSO hybridization and serology
J.K. F CAU GPS
L.S. F CAU GPS
9 Strongly positive
52 Positive
DR3 DR4 DR52
DR53 DQ2
DQ3
DR1 DR2 DQ1
DR2 DR3 DR52
DQ1 DQ2
DR2 DR3 DR52
DQ1 DQ2
DR2 DR4 DR53
DQ1 DQ3
DR2 DR4 DR53
DQ1 DQ3
DR2 DR3 DRS2
DQ1
DR2 DQ1
DR2 DR4 DR53
DQI DQ3
DR2 DR3 DR52
DQ 1
Al A2 B8 B27
BW4 BW6
A2 A3 B7 B35
CW4 BW6
A2 A25 Bl8
B35 CW4
BW6
Al A26 B8 B55
CW3 CW7
BW6
A2 A32 B13
B51 CW2
CW3 BW4
Not Tested
Al A3 B7 849
BW4 BW6
A3 A24 B7 B57
CW6 CW7
BW4 BW6
A2 A3 B35 B51
BW4 BW6
A2 A28 B7 B8
CW7 BW6
Al A31 B8 B60
CW3 BW6
A3 A26 B7 BY
CW7 BW6
Al A3 B7 B8
BW6
Al A3 B7 BY
CW7 BW6
A2 A3 B60 B62
CW3 BW6
A2 A25 B8 B44
CW5 CW7
BW4 BW6
A3 A25 B7 B18
CW7 BW6
A3 A26 B35
B39 CW4
BW6
Al A24 B7 B8
BW6
Al A3 B7 B8
BW6
A2 A24 B7 B60
A23 A29 863
B70 CW7
BW4 BW6
Al A2 B7 138
BW6
Abbreviations are: GN, glomerulonephritis, GPS, Goodpasture's syndrome, GNL, glomerulonephritis with questionable lung involvement.
degrees of pulmonary involvement. The large majority had
complete renal failure requiring dialysis.
HLA Class II DR and DQ typing were performed both
serologically and by molecular techniques using sequence-
specific oligonucleotide probing of amplified DNA. The com-
bined techniques permitted us to confirm the strong association
of anti-GBM nephritis with DR2 [21, 22] and additionally
enabled us to identify the DR2 split DRB1-150l as the SSO-
defined susceptibility allele. The DQB susceptibility allele was
identified to be DQB1-0602. The sample size of our study
population and strong linkage disequilibrium between DRB 1-
1501 and DQB 1-0602 made it impossible to identify which locus
of this presumed haplotype carries the true susceptibility allele.
The prevalence of DR2/DQ6 (21 out of 23 patients) in our
population, though higher than in one study [21] was on the
order of the prevalence of DR2 reported elsewhere: 32 out of 36
patients [23], and 15 out of 17 patients [10].
The DRB 1-0301/DQB 1-020 1 presumed haplotype also
Ethnic
Patient Sex group Diagnosticcategory
Age at
onset
Anti-GBM
highest titer
MolecularRenal failure
req dialysis DRB DRB DQB DQB
Serology
HLA-DR HLA-ABC
B.C. F CAU GPS 22 Positive Yes 0301 0404 0302 0201
B.T. F HIS GPS 13 Positive
B.K. F CAU GPS 26 Positive
C.J. M UNK GPS 54 Positive
D.R. M CAU GPS 28 Positive
No 1501 0101 0602 0501
Yes 1501 — 0602 — DR2 DQ1
Yes 1501 0301 0602 0201 DR2 DR3 DR52
DQ 1
Yes 1501 0403 0602 0302 DR2 DR4 DR53
DQI DQ3
Yes 1501 0103 0602 0501 DR2DQ1
Yes 1501 — 0602 — DR2 DR6 DQ1
Yes 1501 0401 0602 0302 Not TestedN.R. F CAU GPS 51 Positive
P.R. M CAU GPS 37 Positive
R.K. M CAU GPS 18 Positive
R.J. F CAU GPS 20 Strongly positive
T.R. F CAU GPS 27 Positive
T.S. F CAU GPS 20 Strongly positive
U.J. F CAU GPS 32 Positive
W.K. M CAU GPS 37 Weakly positive
B.F. M UNK GNL 60 Positive
D.D. M CAU GNL 20 Positive
M.A. F CAU GNL 25 Positive
A.L. F CAU GN 35 Strongly positive
B.N. M UNK ON 60 Positive
R.R. M CAU GN 56 Positive
R.M. F CAU ON 53 Strongly positive
S.R. M CAU ON 34 Positive
Yes 1501 0301 0602 0201
Yes 1501 0301 0602 0201
Yes 1501 DR4 0602 0302
Yes 1501 0404 0602 0302
Yes 1501 0301 0602 0201
Yes 1501 — 0602 —
Yes 1501 0404 0602 0302
Yes 1501 0301 0602 0201
No 1501 — 0602
Yes 1501 DR4 0602 0302
Yes 1501 0301 0602 0201
Yes 1501 0301 0602 0201
No 1501 0404 0302 0602
No 1501 DR7 0602 0201
No 0101 0301 0501 0201
— DR2DQ1
DR2 DR4 DR53
DQ1 DQ3
DR2 DR3 DR52
DQ1
DR2 DR3 DR52
DQ1 DQ2
DR2 DR4 DR53
DQ1 DQ3
DR2 DR7 DRS3
DQ1
DR1 DR3 DR52
DQ1 DQ2
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Table 3. Estimated allele and haplotype frequencies given for the
U.S. by the 11th International Histocompatibility Workshop
(11th IHWS)
No. patients Expected no.
with observed of patients
alleles with alleles!(N = 23) haplotypes Chi-square
Alleles
DRB1-1501 21 4.5 (0.099)a 7977d
DQB1-0602 21 2.9 (0.065) 129.27"
DRB1-0301 9 4.1 (0.093) 7.13e
DQBI-020l 10 9.8 (0.243) 0.00
All DR4 alleles 8 6.0 (0.140)" 0.90
DRB1-0404 4 1.1 (0.025) 8.03
DQB1-0302 8 3.6 (0.081) 6.38
"Presumed" haplotype
DRB1-1501!DQB1-0602 21 2.5 (0.054) 153.6c
DRB1-0404!DQB1-0302 4 0.87 (0018)f ll.78'
DRB1-0301/DQB1-0201 9 2.4 (0.053) 20.27"
DRBI-OlOl!DQB1-0501 2 2.2 (0.05) 0.02
DRB1-0103/DQB1-0501 1 0.7 (0.015) 0.00
a No. expected equals (p2 + 2pq) N, where p is haplotype!allele
frequency, q is 1-p, and N is total number of patients.b Pooled frequencies for all DR4 molecular subtypes given for the
U.S.
c P < 0.001d P < 0.01
e P < 0.05
No USA data available from workshop. Canadian data substituted
in calculations.
showed significant positive association, and its contribution to
the disease also cannot be attributed to only one loci based
upon the present findings because of sample size and linkage
disequilibrium. While for two of our patients the molecular
subtypes of DR4 could not be unambiguously determined, we
found four patients to be clearly DRB 1-0404. As a single allele
this subtype occurred more frequently among patients. All of
our DR4 patients were DQB1-0302. Considered as a single
allele, DQB1-0302 also appeared to be significantly higher
among patients. Whether this reflects actual risk it confers for
anti-GBM antibody disease or whether its incidence is elevated
due to linkage disequilibrium with the DRB 1-0404 allele cannot
be determined with our sample size. This is an interesting
contrast with the report [21] that the combination DR4/DQ7 was
associated with Goodpasture's syndrome while DR4/DQ8 was
not. The allele associated with DR4 in our population was
DQB1-0302, which is the equivalent of DQ8. Our study using
hybridization with SSOs revealed that only one of the molecular
subtypes of DR4 (DRB 1-0404) was significantly associated with
the disease while others were not.
After analyzing the amino acid sequences of the DQ alleles
which Burns et al [21] found to show strong association with
anti-GBM antibody disease, they suggested that aspartic acid at
position 57 of the DQ beta chain appeared to be important in the
development of the disease. Specifically, in their sample, aspar-
tic acid at position 57 was the only polymorphic amino acid
residue common to both DQI and DQ7 (DQBI-0301), which
were the two DQ types in their study showing strong positive
association. In our study we found no association between DQ7
and disease. This is possibly showing the effect of sampling a
different population or of our sample size, but nonetheless our
data do not lend support to the notion of aspartic acid at residue
57 being of general importance in susceptibility to the disease.
It is still tempting to try to demonstrate that HLA antigens
showing strong positive associations are directly involved in the
pathogenesis of autoimmune diseases by way of their function
of binding and presenting antigenic peptides to T cells. One
hypothesis is that disease susceptibility reflects the ability of the
various allelic forms of HLA antigens to present autoantigens in
a manner that would precipitate an autoimmune reaction.
Another possibility concerns the development of tolerance to
self-antigens by their presentation by HLA molecules to matur-
ing T-cells. By this hypothesis certain HLA molecules might be
less able to bind and present potential autoantigens in the
thymus and therefore result in a less complete deletion of
autoreactive T-cells [24].
We have stated that our sample size and the linkage disequi-
librium between certain alleles at the DR and DQ loci limited
our ability to attribute susceptibility to anti-GBM disease to one
locus or the other. Recent molecular techniques such as RFLP,
SSO probing, and sequencing has made more precise typing of
DQ alleles possible and, as a result, more frequent associations
of autoimmune diseases to the DQ locus have been found [25].
IDDM is clearly one example of this [26], while other examples
include multiple sclerosis [27], rheumatoid arthritis [28], and
coeliac disease [29]. Our observations in this study, especially
with respect to the DQB 1-0602 and DQB 1-0302 alleles, may
indicate that the DQ locus itself merits further examination as a
possible susceptibility factor to anti-GBM disease.
Anti-GBM antibody disease syndrome is notable in that the
autoantigen to which the autoantibodies bind has been charac-
terized [30]. Indeed, an epitope(s) forming the specificity for the
autoantibody has been recently localized to the carboxyl-
terminal region of alpha 3 type IV collagen NC! and encom-
passing residues 198-233 [8], although the other regions of the
alpha 3 type (IV) chain as well as other regions in the NC!
domain of other alpha chains may also react [9, 311. This finding
along with knowledge of the amino acid sequences of the
various susceptibility HLA alleles might present the opportu-
nity for in vitro studies into the possible differential abilities of
the various HLA molecules to present seif-antigenic peptides.
Our determination here that susceptibility to anti-GBM nephri-
tis is restricted to a limited number of molecular subtypes of
HLA class II alleles lends support to this approach.
To determine if genetic susceptibility to anti-GBM glomeru-
lonephritis conferred by the various MHC class II haplotypes
might be recessive, one can see that it is possible for a given
patient in our study to have two, one, or none of the "pre-
sumed" haplotypes that were determined by our calculations
(Table 3) to be of high risk. Fifteen out of our 23 patients
possessed potential susceptibility haplotypes on both their
chromosomes. Based on the frequencies of these haplotypes
given by the 11th IHWS one would expect only 3.0 patients to
have two high-risk "presumed" haplotypes. This excess of
carriers of two "presumed" haplotypes associated with disease
may possibly suggest a recessive mode of action by the suscep-
tibility genetic element.
There is also a basis for hypothesizing that the genes we have
examined here are not themselves responsible for anti-GBM
antibody disease, but are serving as linked genetic markers to
the true disease gene that is located in or near the MHC. We
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observed that associations between MHC class II alleles and
anti-GBM antibody disease seem not to be rigid but might vary
as a function of differences in population frequencies of the
alleles, and that, at least from first observation, susceptibility
cannot be attributed to specific amino acid residues in the
hypervariable regions of the genes examined. Any HLA linked
disease gene might well be immune-related, such as genes
related to processing and transport of peptides [3 2—34] alone or
in combination with HLA determinants.
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